Clinical trial
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent…
NCT00329719 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00329719 |
|---|---|
| Title | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma |
| Official title | A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm |
| Intervention type | Drug, Other, Procedure |
| Interventions | Conventional Surgery, Laboratory Biomarker Analysis, Sorafenib Tosylate, Temsirolimus |
| Enrollment | 115 |
| Start date | Mar 24, 2006 |
| Primary completion | Feb 1, 2013 |
| Completion | Feb 2, 2013 |
| First posted | May 25, 2006 |
| Last update posted | Oct 16, 2018 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: